Investor Relations Home
To access The New England Journal of Medicine publication on the interim results from the ANNEXA-4 study of andexanet, visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1607887 and NEJM ANNEXA-4 Supplement
|There are currently no events scheduled.|
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>
|11/28/16||Portola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition|
|South San Francisco, Calif. (November 28, 2016) – Portola Pharmaceuticals (Nasdaq: PTLA) today announced that clinical and preclinical results from studies of all three of its investigational drugs -- AndexXa™ (andexanet alfa), betrixaban and cerdulatinib -- will be presented at the upcoming 58th American Society of Hematology (ASH) Annual Meeting and Exposition, which is taking place from December 3-6 at the San Diego Convention Center.AndexXa, a U.S. Food and Drug Administration (FDA)-d... |
|11/14/16||Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban|
|NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced results from three substudies of the pivotal Phase 3 APEX Study of betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant in development for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Findings from the analyses were presented by the PERFUSE Study Group at the American Heart Association (AHA) Scientific Sessio... |
|11/07/16||Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update|
|Conference Call Today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today provided a corporate update and reported its financial results for the third quarter ended September 30, 2016.
“We continue to focus on obtaining regulatory approval for our two lead programs in the United States and EU. Both programs have the potential to become the standard of care in two growth areas of thrombosis that have a high unmet ... |
|11/07/16||Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions 2016|
|SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that results of new sub-analyses of the Phase 3 APEX Study of betrixaban, conducted by Dr. C. Michael Gibson and the PERFUSE Study Group, will be presented in oral and poster sessions at the upcoming American Heart Association (AHA) Scientific Sessions 2016, which is taking place from November 12-16 in New Orleans.
Betrixaban, a U.S. Food and Drug Administration (FDA) F... |
|11/02/16||Portola Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 8, at 1:00 p.m. Mountain Standard Time in Scottsdale, Ariz.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Ph... |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.